

What is claimed is:

1. A power supply for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-bradycardia pacing energy to the heart, the power supply comprising:

a capacitor subsystem for storing the anti-bradycardia pacing energy for delivery to the patient's heart; and

a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

2. The power supply of claim 1, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.

3. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 25 volts.

10014360-13301
PATENT "032580"

4. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to approximately 50 volts.

5

5. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.

6. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.

7. The power supply of claim 1, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

20

8. The power supply of claim 7, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

9. The power supply of claim 7, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

10. The power supply of claim 7, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

11. The power supply of claim 7, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

12. The power supply of claim 1, wherein the anti-bradycardia pacing energy comprises a monophasic waveform further comprising a voltage waveform that is either positive or negative in polarity.

13. The power supply of claim 12, wherein the monophasic waveform further comprises a tilt of approximately 5% to approximately 95%.

14. The power supply of claim 13, wherein the tilt is approximately 50%.

5 15. The power supply of claim 1, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 20 to approximately 120 stimuli/minute.

10 16. The power supply of claim 15, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.

15 17. A voltage output system for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-bradycardia pacing energy to the heart, the power
20 supply comprising:

 an energy storage system for storing the anti-bradycardia pacing energy for delivery to the patient's heart; and

an energy source system electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

5 18. The voltage output system of claim 17, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.

10 19. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 25 volts.

15 20. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to approximately 50 volts.

20 21. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.

22. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.

5

23. The voltage output system of claim 17, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

24. The voltage output system of claim 23, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

25. The voltage output system of claim 23, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

26. The voltage output system of claim 23, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

20

27. The voltage output system of claim 23, wherein
the anti-bradycardia pacing energy comprises a monophasic
waveform having a pulse width that is approximately 30
5 milliseconds to approximately 40 milliseconds.

28. The voltage output system of claim 17, wherein
the anti-bradycardia pacing energy comprises a monophasic
waveform that is either positive or negative in polarity.

29. The voltage output system of claim 28, wherein
the positive voltage portion further comprises a tilt of
approximately 5% to approximately 95%.

30. The voltage output system of claim 29, wherein
the tilt is approximately 50%.

31. The voltage output system of claim 17, wherein
the anti-bradycardia pacing energy comprises a monophasic
20 waveform that is provided at a rate of approximately 20 to
approximately 120 stimuli/minute.

001350-13501
TEST-032700

32. The voltage output system of claim 31, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.

5 33. An implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib within a patient, the implantable cardioverter-defibrillator comprising:

 a housing having an electrically conductive surface on an outer surface of the housing;

 a lead assembly electrically coupled to the housing and having an electrode, wherein the lead assembly does not directly contact the patient's heart or reside in the intrathorasic blood vessels;

 a capacitor subsystem located within the housing and electrically coupled to the electrically conductive surface and the electrode for storing anti-bradycardia pacing energy and for delivering the anti-bradycardia pacing energy to the patient's heart through the electrically
20 conductive surface and the electrode; and

 a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

34. The implantable cardioverter-defibrillator of claim 33, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.

5

35. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 25 volts.

36. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to approximately 50 volts.

37. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.

38. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

20

39. The implantable cardioverter-defibrillator of
claim 33, wherein the anti-bradycardia pacing energy
comprises a monophasic waveform having a pulse width that
is approximately 1 millisecond to approximately 40
milliseconds.

40. The implantable cardioverter-defibrillator of
claim 39, wherein the anti-bradycardia pacing energy
comprises a monophasic waveform having a pulse width that
is approximately 1 millisecond to approximately 10
milliseconds.

41. The implantable cardioverter-defibrillator of
claim 39, wherein the anti-bradycardia pacing energy
comprises a monophasic waveform having a pulse width that
is approximately 10 milliseconds to approximately 20
milliseconds.

42. The implantable cardioverter-defibrillator of
claim 39, wherein the anti-bradycardia pacing energy
comprises a monophasic waveform having a pulse width that
is approximately 20 milliseconds to approximately 30
milliseconds.

43. The implantable cardioverter-defibrillator of claim 39, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

44. The implantable cardioverter-defibrillator of claim 33, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

45. The implantable cardioverter-defibrillator of claim 44, wherein the positive voltage portion further comprises a tilt that is approximately 5% to approximately 95%.

46. The implantable cardioverter-defibrillator of claim 45, wherein the tilt is approximately 50%.

47. The implantable cardioverter-defibrillator of claim 33, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 20 to approximately 120 stimuli/minute.

48. The implantable cardioverter-defibrillator of claim 47, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.

49. A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;
storing the anti-bradycardia pacing energy; and
delivering the anti-bradycardia pacing energy to the patient's heart.

50. The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.

51. The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 25 volts.

5

52. The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to approximately 50 volts.

53. The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.

54. The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.

20

55. The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

56. The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 2 milliseconds to approximately 10 milliseconds.

57. The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

58. The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

59. The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.

60. The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

61. The method of claim 60, wherein the positive voltage portion further comprises a tilt of approximately 5% to approximately 95%.

5

62. The method of claim 61, wherein the tilt is approximately 50%.

63. The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 20 to approximately 120 stimuli/minute.

64. The method of claim 63, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.

65. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the third and fifth ribs.

66. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the fourth and sixth ribs.

67. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the sixth and eighth ribs.

5

68. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the eighth and tenth ribs.

69. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the tenth and twelfth ribs.

10
0011360.110501
T050T.092T00